-
Most Recent
Search Results
240 results for frx
2014’s 10 Best Stocks in the S&P 500
Don’t let the S&P 500’s weak 2014 performance fool you — the blue-chip index’s best stocks are a jumpy crowd that cruised 20%-50% in just…
Hertz (HTZ) Gives Carl Icahn 3 Board Seats to Avoid Proxy Battle
Hertz shares rise as the car rental company agrees to give activist investor Carl Icahn 3 board seats.
The Market Rally Resembles a Dog On a Bone
To this point in the year stocks, bonds, gold, oil and gas markets are working just fine, and my charts suggest more to come. Read…
41 S&P 500 Stocks Hit New Lows in Early Tuesday Trading
S&P 500 dips slightly Tuesday, with Urban Outfitters, Abercrombie & Fitch and Citigroup among losers by midday.
MRK: Merck Sells Consumer Business to Double Down on Blockbusters
Swinging for the fences, MRK sold one of the industry’s crown jewels in exchange for an opportunity to find new blockbuster drugs. It’s a risky…
Is Big Pharma Resistant to Antibiotics?
Less profitable drugs take a backseat despite health risks
Actavis Prescribes Profits via M&A and Generic Drugs
This specialty pharmaceutical company is consolidating its way into becoming a post-Affordable Care Act powerhouse.
No Payday In Sight for Alzheimer’s Drug Stocks
At best, the drugs on the market are stopgap measures. They can’t cure the disease.
Is it Time to Follow Ichan Out of Amgen — and Other Biotechs?
Investor Carl Ichan recently dumped several biotechs. However, Amgen’s sales are strong, and with other positives, it’s possible he cut bait too soon.
Best of 2025: The Rise of the “New Market Aristocrats”… and How to Join Them
Thanks to AI, the financial chasm between folks is expanding by the day and creating a growing roster of new market aristocrats, along with extreme…
Johnson & Johnson, Forest Labs Will Make You Sick
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both…
2 Biotech Stocks to Buy After Earnings
Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy.
Wall Street’s 10 Biggest Deals of Q1 2014
The year is off to a hot start for M&A, as Facebook, Google, IBM and others got busy pulling off Q1’s biggest deals.
3 Mutual Funds Poised to Profit From Obamacare
By Bill Wysor — There are winners and losers in the changing healthcare industry, but let seasoned mutual fund managers do the legwork for you.
Buy Icahn Enterprises to Play Apple Stock with Less Risk
For a low-risk way to play a bounce back in Apple stock, let Carl Icahn and a bet on Icahn Enterprises stock lead the way.
4 Best Mutual Funds at Vanguard Now
Here are four of the top mutual fund investments from Vanguard now.
Celebrity SPAC Merger News: 10 Stars Jumping on the SPAC Bandwagon
Investors should follow the latest celebrity SPAC merger news to see where money is moving. Here’s some of the top stars in the game.
Will 2014’s Top Performers Keep Performing?
These three stocks are likely to run higher, given both valuation and business environment.
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here’s our new research on 50 stocks in Portfolio…
Maintain Realistic Expectations
The most that can be expected is a small rally and more sideways movement.
America’s AI Overhaul Has Begun — and Workers Aren’t Prepared
In today’s Sunday Digest takeover, our technology expert Luke Lango lays out a case for why AI isn’t just transforming technology or markets — it’s…
3 Funds to Play the Healthcare Megatrend
Healthcare has been hot in 2013, but more importantly, it’s set up to be a huge mover going forward thanks to several big trends. Here’s…
6 – 10 of 240 results
